Market Cap ₹954 Cr.
Stock P/E 73.5
P/B 2.8
Current Price ₹612.9
Book Value ₹ 220.9
Face Value 5
52W High ₹890.1
Dividend Yield 0.08%
52W Low ₹ 498
Shivalik Rasayan Ltd is engaged in supplying agrochemicals. The Company is a producer of organ phosphorous (OP)-primarily based insecticides and chemical substances. It additionally manufactures organophosphate pesticides, including Dimethoate Technical and Malathion Technical. Its Dimethoate technical is utilized in preparation of formulations used within the manage of various insect pests and mites. It is an OP-based systemic insecticide and also possesses properties of an acaricide and a contact insecticide. It is an insecticide of moderate mammalian toxicity, that is used in opposition to piercing sucking insects, spider mites, chewing mining and dull insects on cereals and cotton, amongst others. Its Malathion Technical is a non-systemic, spectrum OP-primarily based contact insecticide. It is used in the agricultural manufacturing of a number of meals/feed crops. It controls insects, together with aphids, leafhoppers, spider mites, scale bugs, housefly and mosquitoes, in addition to a number of other sucking and chewing insects.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
#(Fig in Cr.) | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 |
---|---|---|---|---|---|---|---|---|---|---|
Net Sales | 57 | 60 | 48 | 58 | 56 | 57 | 63 | 64 | 67 | 70 |
Other Income | 0 | 1 | 2 | 1 | 1 | 1 | 1 | 0 | 1 | 2 |
Total Income | 57 | 61 | 50 | 59 | 57 | 59 | 64 | 65 | 68 | 72 |
Total Expenditure | 45 | 48 | 38 | 46 | 45 | 47 | 53 | 53 | 57 | 61 |
Operating Profit | 12 | 13 | 12 | 13 | 12 | 11 | 11 | 12 | 10 | 10 |
Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 |
Depreciation | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Profit Before Tax | 9 | 10 | 8 | 9 | 8 | 7 | 7 | 8 | 5 | 6 |
Provision for Tax | 1 | 1 | 0 | 1 | 1 | 1 | -0 | 1 | 2 | 1 |
Profit After Tax | 9 | 8 | 8 | 8 | 8 | 7 | 7 | 6 | 3 | 4 |
Adjustments | -2 | -2 | -2 | -2 | -2 | -2 | -4 | -2 | -1 | -1 |
Profit After Adjustments | 6 | 6 | 7 | 6 | 6 | 5 | 3 | 4 | 2 | 3 |
Adjusted Earnings Per Share | 4.4 | 4.3 | 4.5 | 4.4 | 3.8 | 3.3 | 2.3 | 2.9 | 1.2 | 2 |
#(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM |
---|---|---|---|---|---|---|---|---|---|---|
Net Sales | 41 | 110 | 123 | 155 | 171 | 186 | 198 | 215 | 234 | 264 |
Other Income | 0 | 1 | 1 | 3 | 8 | 3 | 1 | 4 | 5 | 4 |
Total Income | 42 | 111 | 124 | 158 | 179 | 189 | 199 | 218 | 239 | 269 |
Total Expenditure | 38 | 99 | 105 | 131 | 147 | 157 | 159 | 167 | 191 | 224 |
Operating Profit | 3 | 12 | 19 | 27 | 32 | 32 | 40 | 51 | 48 | 43 |
Interest | 0 | 5 | 6 | 4 | 3 | 2 | 2 | 3 | 5 | 6 |
Depreciation | 0 | 2 | 2 | 2 | 3 | 4 | 9 | 11 | 12 | 12 |
Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Profit Before Tax | 3 | 5 | 11 | 20 | 26 | 27 | 29 | 37 | 32 | 26 |
Provision for Tax | 1 | 2 | 3 | 5 | 5 | 5 | 4 | 3 | 2 | 4 |
Profit After Tax | 2 | 3 | 8 | 15 | 21 | 22 | 25 | 34 | 30 | 20 |
Adjustments | 0 | 0 | -3 | -6 | -7 | -8 | -7 | -9 | 0 | -8 |
Profit After Adjustments | 2 | 3 | 5 | 9 | 14 | 14 | 18 | 26 | 30 | 12 |
Adjusted Earnings Per Share | 0 | 3.7 | 6.4 | 8.6 | 9.9 | 10.2 | 12.8 | 17.7 | 20.6 | 8.4 |
# | 1 Year | 3 Year | 5 Year | 10 Year |
---|---|---|---|---|
Sales CAGR | 9% | 8% | 9% | 0% |
Operating Profit CAGR | -6% | 14% | 12% | 0% |
PAT CAGR | -12% | 11% | 15% | 0% |
# | 1 Year | 3 Year | 5 Year | 10 Year |
---|---|---|---|---|
Share Price CAGR | -14% | -5% | 18% | NA% |
ROE Average | 10% | 14% | 15% | 27% |
ROCE Average | 10% | 14% | 16% | 25% |
#(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
---|---|---|---|---|---|---|---|---|---|
Shareholder's Funds | 11 | 14 | 11 | 49 | 165 | 176 | 179 | 287 | 360 |
Minority's Interest | 0 | 1 | 16 | 45 | 54 | 73 | 80 | 77 | 59 |
Borrowings | 0 | 11 | 12 | 7 | 5 | 3 | 11 | 8 | 13 |
Other Non-Current Liabilities | 0 | 2 | 2 | 2 | 2 | 1 | 2 | 1 | -1 |
Total Current Liabilities | 11 | 52 | 54 | 49 | 62 | 75 | 91 | 113 | 144 |
Total Liabilities | 23 | 81 | 94 | 152 | 288 | 328 | 363 | 487 | 575 |
Fixed Assets | 7 | 27 | 27 | 40 | 41 | 52 | 210 | 221 | 218 |
Other Non-Current Assets | 1 | 2 | 3 | 4 | 32 | 109 | 8 | 11 | 65 |
Total Current Assets | 14 | 51 | 63 | 106 | 212 | 158 | 131 | 240 | 262 |
Total Assets | 23 | 81 | 94 | 152 | 288 | 328 | 363 | 487 | 575 |
#(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
---|---|---|---|---|---|---|---|---|---|
Opening Cash & Cash Equivalents | 0 | 7 | 3 | 5 | 26 | 95 | 9 | 5 | 71 |
Cash Flow from Operating Activities | 4 | 12 | 8 | -7 | -8 | 6 | 59 | 11 | -19 |
Cash Flow from Investing Activities | -0 | -18 | -4 | -24 | -24 | -102 | -65 | -23 | -71 |
Cash Flow from Financing Activities | 1 | 3 | -3 | 52 | 100 | 10 | 2 | 78 | 50 |
Net Cash Inflow / Outflow | 4 | -3 | 2 | 21 | 69 | -86 | -4 | 66 | -40 |
Closing Cash & Cash Equivalent | 4 | 3 | 5 | 26 | 95 | 9 | 5 | 71 | 31 |
# | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
---|---|---|---|---|---|---|---|---|---|
Earnings Per Share (Rs) | 0 | 3.68 | 6.39 | 8.63 | 9.88 | 10.16 | 12.77 | 17.67 | 20.59 |
CEPS(Rs) | 2.32 | 6.34 | 12.59 | 16.78 | 17.4 | 18.55 | 24.13 | 31.25 | 28.6 |
DPS(Rs) | 0 | 0 | 0.5 | 0.5 | 0.5 | 0.25 | 0.5 | 0.5 | 0.5 |
Book NAV/Share(Rs) | 0 | 15.78 | 11.56 | 45.32 | 117.19 | 120.81 | 119.7 | 180.88 | 216.95 |
Core EBITDA Margin(%) | 6.1 | 9.02 | 14.29 | 15.39 | 13.91 | 15.53 | 19.44 | 22.04 | 18.53 |
EBIT Margin(%) | 6.61 | 8.14 | 13.14 | 15.51 | 16.82 | 15.34 | 15.67 | 18.64 | 15.57 |
Pre Tax Margin(%) | 5.87 | 4.08 | 8.8 | 12.94 | 15.34 | 14.33 | 14.64 | 17.21 | 13.5 |
PAT Margin (%) | 3.89 | 2.73 | 6.58 | 9.74 | 12.28 | 11.83 | 12.48 | 15.95 | 12.72 |
Cash Profit Margin (%) | 4.28 | 4.71 | 8.37 | 11.27 | 14.05 | 13.72 | 16.83 | 21.08 | 17.67 |
ROA(%) | 7.89 | 6.07 | 9.67 | 12.4 | 9.52 | 7.15 | 7.14 | 8.06 | 5.62 |
ROE(%) | 17.48 | 26.44 | 72.4 | 52.98 | 20.02 | 13.44 | 14.88 | 16.05 | 10.35 |
ROCE(%) | 28.55 | 34.23 | 39.5 | 43.66 | 22.8 | 15.87 | 16.59 | 15.76 | 10.31 |
Receivable days | 70.92 | 51.11 | 77 | 89.81 | 105.03 | 107.99 | 117.32 | 118 | 120.48 |
Inventory Days | 3.28 | 19.83 | 38.72 | 37.3 | 41.01 | 40.77 | 27.65 | 40.75 | 88.07 |
Payable days | 125.55 | 99.54 | 137.23 | 101.86 | 97.5 | 128.93 | 155.56 | 194.02 | 192.82 |
PER(x) | 0 | 7.85 | 15.76 | 31.65 | 27.33 | 21.74 | 55.23 | 52.79 | 32.66 |
Price/Book(x) | 0 | 1.83 | 8.72 | 6.03 | 2.3 | 1.83 | 5.89 | 5.16 | 3.1 |
Dividend Yield(%) | 0 | 0 | 0.4 | 0.15 | 0.19 | 0.11 | 0.07 | 0.05 | 0.07 |
EV/Net Sales(x) | -0.01 | 0.47 | 0.91 | 1.83 | 1.74 | 1.65 | 5.05 | 6.16 | 4.3 |
EV/Core EBITDA(x) | -0.16 | 4.46 | 5.88 | 10.62 | 9.37 | 9.58 | 25.22 | 25.9 | 20.97 |
Net Sales Growth(%) | 0 | 166.02 | 12.31 | 25.72 | 9.94 | 9.22 | 6.07 | 8.69 | 9.17 |
EBIT Growth(%) | 0 | 205.62 | 80.08 | 43.89 | 18.06 | -0.41 | 8.4 | 29.27 | -8.8 |
PAT Growth(%) | 0 | 74.34 | 168.57 | 80.22 | 37.33 | 5.27 | 11.88 | 38.92 | -12.93 |
EPS Growth(%) | 0 | 0 | 73.48 | 35.07 | 14.39 | 2.92 | 25.68 | 38.34 | 16.51 |
Debt/Equity(x) | 0.04 | 2.27 | 3.19 | 0.46 | 0.13 | 0.07 | 0.18 | 0.16 | 0.21 |
Current Ratio(x) | 1.28 | 0.97 | 1.16 | 2.17 | 3.44 | 2.11 | 1.44 | 2.12 | 1.82 |
Quick Ratio(x) | 1.25 | 0.74 | 0.88 | 1.83 | 3.09 | 1.84 | 1.33 | 1.81 | 1.34 |
Interest Cover(x) | 8.92 | 2.01 | 3.03 | 6.04 | 11.42 | 15.26 | 15.2 | 13.07 | 7.53 |
Total Debt/Mcap(x) | 0 | 1.24 | 0.37 | 0.08 | 0.05 | 0.04 | 0.03 | 0.03 | 0.07 |
# | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
---|---|---|---|---|---|---|---|---|---|---|
Promoter | 50.32 | 50.32 | 50.32 | 50.32 | 50.32 | 50.32 | 50.05 | 47.95 | 47.95 | 47.95 |
FII | 0 | 0.06 | 0.04 | 0.01 | 0.01 | 0.01 | 0.35 | 0.66 | 1.18 | 1.87 |
DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.24 | 0.59 | 2.01 |
Public | 49.68 | 49.62 | 49.64 | 49.66 | 49.67 | 49.67 | 49.6 | 51.14 | 50.28 | 48.17 |
Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
# | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
---|---|---|---|---|---|---|---|---|---|---|
Promoter | 0.73 | 0.73 | 0.73 | 0.73 | 0.73 | 0.73 | 0.75 | 0.75 | 0.75 | 0.75 |
FII | 0 | 0 | 0 | 0 | 0 | 0 | 0.01 | 0.01 | 0.02 | 0.03 |
DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.01 | 0.03 |
Public | 0.72 | 0.72 | 0.72 | 0.72 | 0.72 | 0.72 | 0.74 | 0.8 | 0.78 | 0.75 |
Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 1.45 | 1.45 | 1.45 | 1.45 | 1.45 | 1.45 | 1.49 | 1.56 | 1.56 | 1.56 |
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
---|
Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
---|
Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
---|
Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
---|
Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
---|
You May Also Know About